UK Fundholding Savings Doubts

24 July 1997

While fundholding general practices in Northern Ireland containedprescribing costs more effectively in their first year than non-fundholders, partly by increasing generic prescribing, these savings declined over time, according to a study in the British Medical Journal (July 19).

By the third year, the earliest group of fundholders showed a yearly percentage increase in prescribing costs that was virtually the same as that for non-fundholders. The study authors, Therese Rafferty of the University of Belfast et al, say this finding may suggest "that the incentive for making further savings has diminished after the first two years of fundholding."

The reason, they say, is that fundholders' budgets are reset each year to reflect not only savings but also pay and price rises. Savings are deducted from the reset, which "makes it increasingly difficult to make further changes each year, and may also reduce the incentive to so do."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight